Management of infections in the neutropenic patient

Annual Review of Medicine

Volumn 55, Issue , 2004, Pages 519-526

  Rolston, Kenneth V I ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Bacterial fungal infections; Empiric therapy; Infection prevention; Risk assessment

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CARBAPENEM; CEPHALOSPORIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CLOSTRIDIUM SEPTICUM; DRUG RESPONSE; FEBRILE NEUTROPENIA; FUNGICIDAL ACTIVITY; HUMAN; IMMUNOCOMPETENT CELL; INFECTION CONTROL; INFECTION PREVENTION; MYCOSIS; OPPORTUNISTIC INFECTION; PNEUMONIA; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; URINARY TRACT INFECTION;

BACTERIAL INFECTIONS; HUMANS; MYCOSES; NEUTROPENIA; VIRUS DISEASES;

EID: 1542358941     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.55.091902.103826     Document Type: Review

References (23)

1. Bodey GP, Buckley M, Sathe YS, et al. 1966. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann. Intern. Med. 64:328-40
2. Hughes WT, Armstrong D, Bodey GP, et al. 2002. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis. 34:730-51
3. Rolston KVI, Bodey GP. 2003. Infections in patients with cancer. In Cancer Medicine, ed. JF Holland, E Frei, pp. 2633-58. Ontario: BC Decker. 6th ed.
4. Rolston KVI. 1998. Expanding the options for risk-based therapy in febrile neutropenia. Diagn. Microbiol. Infect. Dis. 31:411-16
5. Sickles EA, Greene WH, Wiernik PH. 1975. Clinical presentation of infection in granulocytopenic patients. Arch. Intern. Med. 135:715-19
6. Gomez L, Martino R, Rolston KV. 1998. Neutropenic enterocolitis: spectrum of the disease and comparison of definite and possible cases. Clin. Infect. Dis. 27:695-99
7. Rolston KVI, Bodey GP. 1993. Diagnosis and management of perianal and perirectal infection in the granulocytopenic patient. In Current Clinical Topics in Infectious Diseases, ed. J Remington, MN Swartz, pp. 164-71. Boston: Blackwell Sci.
8. Rolston K. 1999. New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clin. Infect. Dis. 29:515-21
9. Talcott JA, Siegel RD, Finberg R, et al. 1992. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J. Clin. Oncol. 10:316-22
10. Klastersky J, Paesmans M, Rubenstein E, et al. 2000. The MASCC Risk Index: a multinational scoring system to predict low-risk febrile neutropenic cancer patients. J. Clin. Oncol. 18:3038-51
11. Zinner SH. 1999. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin. Infect. Dis. 29:490-94
12. Elting LS, Bodey GP, Fainstein V. 1986. Polymicrobial septicemia in the cancer patient. Medicine 65:218-25
13. Jones RN. 1999. Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia. Clin. Infect. Dis. 29:495-502
14. Rolston KVI, Kontoyiannis DP, Raad II, et al. 2003. Susceptibility surveillance among gram-negative bacilli at a comprehensive cancer center. Presented at Gen. Meet. Am. Soc. Microbiol., 103rd, Washington, DC, May 18-22 (Abstr. #2362)
15. Walsh TJ, Pappas P, Winston DJ, et al. 2002. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. 346:225-34
16. Freifeld A, Marchigiani D, Walsh T, et al. 1999. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N. Engl. J. Med. 341:305-11
17. Kern WV, Cometta A, DeBock R, et al. 1999. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N. Engl. J. Med. 341:312-18
18. Rubenstein EB, Rolston K, Benjamin RS, et al. 1993. Outpatient treatment of febrile episodes in low risk neutropenic cancer patients. Cancer 11:3640-46
19. Mullen CA, Petropoulos D, Roberts WM, et al. 1999. Outpatient treatment of febrile neutropenia in low risk pediatric cancer patients. Cancer 86:126-34
20. Cruciani M, Rampazzo R, Malena M, et al. 1996. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin. Infect. Dis. 23:795-805
21. Rolston KVI. 1998. Commentary: chemoprophylaxis and bacterial resistance in neutropenic patients. Infect. Dis. Clin. Pract. 7:202-4
22. Goodman JL, Winston DJ, Greenfield A, et al. 1992. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med. 326:845-51
23. Marr KA, Seidel K, White TC, et al. 2000. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J. Infect. Dis. 181:309-16